Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating the safety of shortened infusion times for oncological immunotherapies
2022-003588-55Phase 4Active
- Sponsor
- Isala
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab, trastuzumab, durvalumab, pembrolizumab, nivolumab and 3 more in cancer, sponsored by Isala. Primary endpoints: Incidence and grading of infusion-related and hypersensitivity reactions per drug, Intra-individual variation in plasma levels of monoclonal antibodies and 1 more. Started Oct 2024; status: active.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on 2022-003588-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003588-55.